Citi Sticks To These Pharma Stocks Amid Trump's 25% Tariff Plans
The US President Donald Trump intending to impose 25% tariff on pharmaceuticals imports has added to the uncertainty for the Indian pharma stocks, Citi Research...
The US President Donald Trump intending to impose 25% tariff on pharmaceuticals imports has added to the uncertainty for the Indian pharma stocks, Citi Research...
Read More
Other Stories in Business
- Top Mutual Funds Buy and Sell in Stocks
- Decline in Portfolio of Prominent Investors
- Gold Price At Rs 85,920 After High — Check Rates In Mumbai, Bengaluru, Delhi, Chennai And More
- Why I’m Back on Medium (A Data Analyst’s Plot Twist)
- Repo rate relief? Big surprise for big business as banks dither on lowering lending rates
- RSS' swanky headquarters spans over 5-lakh sq ft, gets auditorium named after Ashok Singhal. Details here
- AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript
- Taiwan and TSMC scramble to head off Donald Trump’s tariff threat
- 'Threat has become invisible': Tech millionaire Bryan Johnson on India’s air pollution problem
